Advocated to preserve the BioShield Special Reserve Fund (SRF) – critical source of funding for MCM development and procurement – and successfully advocated against at least 3 proposed Congressional “raids” (up to $2 billion) of the SRF.
January 1, 2014
January 1, 2015
Successfully advocated for five-year reauthorization of BARDA and SRF in the Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA).
January 1, 2015
January 1, 2015
Served as trusted resource for Congressional staff working to better integrate FDA into the MCM development process; secured strong legislative changes in PAHPRA.
January 1, 2015
January 1, 2015
Constructively engaged with FDA on critical policy/regulatory issues related to development of MCMs, including animal models. During 2012, the Alliance was invited by FDA to (i) participate in a “hot topics” educational briefing for FDA reviewers and other professionals, and (ii) provide perspectives on GLP issues when conducting animal model studies in BSL-3 and BSL-4 Labs.
January 1, 2015
January 1, 2015
Convened an informal coalition of stakeholders (including public health and national defense organizations) committed to the long term success of the US government’s biodefense and public health preparedness enterprise to strengthen education and outreach efforts.
